Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 6/2020

Open Access 01-06-2020 | Vulgar Psoriasis | Original Research

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

Authors: Uta Kiltz, Petros P. Sfikakis, Karl Gaffney, Paul-Gunther Sator, Ralph von Kiedrowski, Andreas Bounas, Nicola Gullick, Curdin Conrad, Dimitris Rigopoulos, Eric Lespessailles, Marco Romanelli, Pierre-Dominique Ghislain, Jan Brandt-Jürgens, Rasho Rashkov, Maher Aassi, Roberto Orsenigo, Chiara Perella, Effie Pournara, Sven Gathmann, Piotr Jagiello, Justyna Veit, Matthias Augustin

Published in: Advances in Therapy | Issue 6/2020

Login to get access

Abstract

Introduction

Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action, sustained long-term clinical responses and a consistently favourable safety profile across phase 3 trials. Here, we report the clinical data at enrolment from SERENA, designed to investigate the real-world use of secukinumab across all three indications.

Methods

SERENA is an ongoing, longitudinal, observational study conducted at 438 sites across Europe in patients with moderate to severe plaque PsO, active PsA or active AS. Patients should have received at least 16 weeks of secukinumab treatment before enrolment in the study.

Results

Overall 2800 patients were included in the safety set; patients with PsA (N = 541) were older than patients with PsO (N = 1799) and patients with AS (N = 460); patients with PsO had a higher mean body weight than patients with PsA and patients with AS; and patients with PsO and patients with AS were predominantly male. Time since diagnosis was longer in patients with PsO compared with patients with PsA and patients with AS, and about 40% of patients were either current or former smokers. The proportion of obese patients (body mass index ≥ 30 kg/m2) was similar across indications. Patients were treated with secukinumab for a mean duration of 1 year prior to enrolment (range 0.89–1.04). The percentages of patients with prior biologics exposure were 31.5% PsO, 59.7% PsA and 55% AS. The percentages of patients prescribed secukinumab monotherapy were 75% (n = 1349) in PsO, 48.2% (n = 261) in PsA and 48.9% (n = 225) in AS groups.

Conclusion

Baseline demographics of the study population are consistent with existing literature. This large observational study across all secukinumab indications will provide valuable information on the long-term effectiveness and safety of secukinumab in the real-world setting.
Appendix
Available only for authorised users
Literature
1.
Schreiber S, Colombel J-F, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473–9.PubMedCrossRef
2.
Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.PubMed
3.
Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007;56(4):1051–66.PubMedCrossRef
4.
Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863–72.PubMedCrossRef
5.
Avaloz-Diaz E, Dominguez-Cherit J, Herrera-Esparza R. Cutaneous manifestations of spondyloarthritis. Int J Clin Rheumatol. 2012;7(1):55–61.CrossRef
6.
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–20.PubMedCrossRef
7.
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7.PubMedCrossRef
8.
Wervers K, Luime JJ, Tchetverikov I, et al. Influence of disease manifestations on health-related quality of life in early psoriatic arthritis. J Rheumatol. 2018;45(11):1526–31.PubMedCrossRef
9.
Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857–72.PubMedCrossRef
10.
11.
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Dermato-venereol. 2010;90(2):147–51.CrossRef
12.
von Stebut E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–62.CrossRef
13.
Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–5.PubMedCrossRef
14.
Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):677–98.CrossRef
15.
Molto A, Dougados M. Comorbidities in spondyloarthritis including psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):390–400.PubMedCrossRef
16.
17.
Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–5.PubMedCrossRef
18.
Radtke MA, Langenbruch AK, Schafer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1–6.PubMed
19.
Menter A. Psoriasis and psoriatic arthritis overview. Am J Managed Care. 2016;22(8 Suppl):s216–s224224.
20.
Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther (Heidelb). 2018;8(4):509–25.PubMedCrossRef
21.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.PubMedCrossRef
22.
Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65.e19.PubMedCrossRef
23.
Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–40.PubMedCrossRef
24.
25.
Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70(1):146–67.PubMedCrossRef
26.
Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatol Treat. 2019:1–8. https://​doi.​org/​10.​1080/​09546634.​2019.​1671577.
27.
Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheumatic Dis. 2009;68(Suppl 2):ii1–44.CrossRef
28.
Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol. 2014;28(5):663–72.PubMedCrossRef
29.
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–733.PubMedCrossRef
30.
31.
Olivieri I, D'Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9):531–42.PubMedCrossRef
32.
Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054–63.PubMedCrossRef
33.
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73.PubMedCrossRef
34.
Mielants H, Van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S56–61.PubMed
35.
Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009;48(9):1029–35.PubMedCrossRef
36.
Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650–7.PubMedCrossRef
37.
Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;30(2):95–103.PubMedCrossRef
38.
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discovery. 2012;11(10):763–76.PubMedCrossRef
39.
Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–50.PubMedCrossRef
40.
Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de Kerkhof PC. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799–803.PubMedCrossRef
41.
42.
43.
Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP. Osteoclastogenesis and arthritis. Clin Exp Med. 2011;11(3):137–45.PubMedCrossRef
44.
Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med. 2012;18(7):1018–9.PubMedCrossRef
45.
Louie GH, Ward MM. Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol. 2014;26(2):145–50.PubMedPubMedCentralCrossRef
46.
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.PubMedCrossRef
47.
McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.PubMedCrossRef
48.
Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–13.PubMedCrossRef
49.
Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–14.PubMedPubMedCentralCrossRef
50.
Langley RG, Sigurgeirsson B, Szepietowski JC, et al. Secukinumab maintains improvements in psoriasis through five years of treatment: a randomized extension of the phase III ERASURE and FIXTURE trials. Oral presentation at American Academy of Dermatology (AAD) Annual Meeting, Mar 1–5, 2019, Washington D.C., USA.
51.
McInnes IB, Kivitz AJ, Nash P, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: long-term (4-year) data from a phase 3 study. Poster presented at The American College of Rheumatology (ACR) Annual Meeting, October 19–24, 2018, Chicago, USA.
52.
Marzo-Ortega H, Sieper J, Kivitz AJ, et al. Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with consistent safety profile and high retention rate: 4-year results from a phase III trial. Poster presented at The American College of Rheumatology (ACR) Annual Meeting, October 19–24, 2018, Chicago, USA.
53.
Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74.PubMedPubMedCentralCrossRef
54.
Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthcare. 2018;11:295–304.CrossRef
55.
Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213.PubMedPubMedCentralCrossRef
56.
COSENTYX [Summary of Product Characteristics]. Camberley, UK: Novartis Europharm Limited. 2019.
57.
Korber A, Thaci D, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, et al. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2018;32(3):411–9.PubMedCrossRef
58.
Thaci D, Korber A, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34:310–8.
59.
Kiltz U, Legeler C, Maier-Peuschel M, Mann C, Tony H-P. Baseline characteristics of patients with ankylosing spondylitis and psoriatic arthritis treated with secukinumab in the real-world setting: AQUILA, a non-interventional study. Open Rheumatol J. 2019;13:53–60.CrossRef
60.
Papp KA, Gooderham M, Beecker J, et al. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatol. 2019;19(1):9.PubMedPubMedCentralCrossRef
61.
Mann HF, Zavada J, Senolt L, et al. Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clin Exp Rheumatol. 2019;37(2):342–3.PubMed
62.
63.
Blauvelt A, Reich K, Tsai T-F, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60–9.e9.PubMedCrossRef
64.
Mease P, van der Heijde D, Landewe R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–7.PubMed
65.
Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatol Treat. 2003;14(3):158–65.CrossRef
66.
67.
Gladman DD, Mease PJ, Krueger G, et al. Outcome measures in psoriatic arthritis. J Rheumatol. 2005;32(11):2262–9.PubMed
68.
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63(S11):S64–S85.
69.
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63(S11):S240–S252252.CrossRef
70.
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686–91.PubMedCrossRef
71.
Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res. 2011;63(S11):S47–S58.CrossRef
72.
Machado PMMC, Landewé RBM, van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol. 2011;38(7):1502–6.PubMedCrossRef
73.
Knop C, Oeser M, Bastian L, Lange U, Zdichavsky M, Blauth M. Development and validation of the Visual Analogue Scale (VAS) Spine Score. Unfallchirurg. 2001;104(6):488–97.PubMedCrossRef
74.
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheumatic Dis. 2003;62(2):127–32.CrossRef
75.
Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48.PubMedCrossRef
76.
Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39.PubMedCrossRef
77.
Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–93.PubMedCrossRef
78.
Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847–56.PubMedCrossRef
79.
Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–90.PubMedCrossRef
80.
Bonomo L, Abittan BJ, Hashim PW, Karki C, Mason M, Lebwohl M. Combination use of systemic therapies in psoriasis: baseline characteristics from the Corrona Psoriasis Registry. J Drugs Dermatol. 2019;18(8):731–40.PubMed
81.
Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5(1):e000880.PubMedPubMedCentralCrossRef
82.
Mease PJ, Karki C, Liu M, et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open. 2018;4(1):e000638.PubMedPubMedCentralCrossRef
Metadata
Title
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Authors
Uta Kiltz
Petros P. Sfikakis
Karl Gaffney
Paul-Gunther Sator
Ralph von Kiedrowski
Andreas Bounas
Nicola Gullick
Curdin Conrad
Dimitris Rigopoulos
Eric Lespessailles
Marco Romanelli
Pierre-Dominique Ghislain
Jan Brandt-Jürgens
Rasho Rashkov
Maher Aassi
Roberto Orsenigo
Chiara Perella
Effie Pournara
Sven Gathmann
Piotr Jagiello
Justyna Veit
Matthias Augustin
Publication date
01-06-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01352-8

Other articles of this Issue 6/2020

Advances in Therapy 6/2020 Go to the issue

Original Research

A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies

Original Research

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

Review

Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review

Original Research

The Relationship Between White Adipose Tissue Inflammation and Overweight/Obesity in Chinese Female Breast Cancer: A Retrospective Study

Original Research

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Original Research

A Novel Nomogram Integrated with Inflammation-Based Factors to Predict the Prognosis of Gastric Cancer Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits